** Medical device maker Stryker SYK.N rise 1.2% to $395
** Brokerage Citi Research resumes coverage on SYK with "buy" rating; sets PT at $450, 15.3% upside to the stock's last close
** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)
** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says
** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.
** Citi calls the Inari acquisition "another step in SYK evolution"
** Stock has risen 10.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。